SCHEMBL3309743

SCHEMBL3309743

CCOC(=O)N(C(=O)c1cccc2c1CCN(C(=O)OC(C)(C)C)C2)C1Cc2ccccc2C1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.44
NR1D1 P20393 1/20 0.42
MAPK1 P28482 1/20 0.41
ADORA1 P30542 1/20 0.41
ESR2 Q92731 1/20 0.40
NR1H2 P55055 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
NAMPT P43490 3/20 0.39
SCN9A Q15858 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ABHD6 Q9BV23 1/20 0.38
LIPG Q9Y5X9 1/20 0.38
THRB P10828 1/20 0.38
F12 P00748 2/20 0.37
GPR119 Q8TDV5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3304095 0.93 NR1D1 (0.42) UCHL1NR1D1MAPK1ADORA1ESR2
SCHEMBL3311068 0.88 UCHL1 (0.49) UCHL1MAPK1ESR2NR1H2DDB1
SCHEMBL3307223 0.80 ESR2 (0.43) UCHL1MAPK1ESR2NR1H2DDB1
SCHEMBL30647075 0.76 UCHL1 (0.53) UCHL1MAPK1ADORA1ESR2NR1H2
SCHEMBL1857142 0.76 UCHL1 (0.53) UCHL1MAPK1ADORA1ESR2NR1H2
SCHEMBL4787883 0.75 NR1H2 (0.54) UCHL1MAPK1ADORA1ESR2NR1H2
SCHEMBL3309736 0.74 CXCR5 (0.43) UCHL1MAPK1ADORA1ESR2NR1H2
SCHEMBL21807308 0.74 UCHL1 (0.54) UCHL1MAPK1ADORA1ESR2NR1H2
SCHEMBL10289745 0.73 ESR2 (0.53) UCHL1MAPK1ADORA1ESR2NR1H2
SCHEMBL20558294 0.73 ADORA1 (0.51) MAPK1ADORA1ESR2NR1H2DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569535-B2 Substituted benzoylamino-indan-2-carboxylic acids and related compounds SANOFI (FR) 2013-10-29 US disclosed
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
EP-2155711-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS Sanofi-Aventis (FR) 2010-02-24 EP disclosed
WO-2008151211-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS SANOFI-AVENTIS (FR) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113462-A1 SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS CXCR5, CXCR1, CCR5 UCHL1 4176/4885NR1D1 554/4885MAPK1 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.